AdAlta Ltd (ASX:1AD) CEO and managing director Tim Oldham speaks with Andrew Scott from Proactive about teaming up with clinical-stage biotech GPCR Therapeutics to investigate a new cancer treatment approach. Oldham explains what each company will contribute to the partnership and how this fits in with work done so far on AD-214. An update on the AD-214 strategy is due in the next 10 days.
AdAlta teams up with clinical-stage biotech GPCR Therapeutics
